학술논문

POSA117 Cost-Effectiveness Analysis of Third-Line Pazopanib Versus Regorafenib for Metastatic or Unresectable Gastrointestinal Stromal Tumors in China
Document Type
Abstract
Source
In Value in Health January 2022 25(1) Supplement:S56-S56
Subject
Language
ISSN
1098-3015